OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Mechanism of Action of Ropeginterferon Alfa-2b in Polycythemia Vera Treatment
Albert Qin
Clinical Therapeutics (2024) Vol. 46, Iss. 5, pp. 439-440
Closed Access | Times Cited: 8
Albert Qin
Clinical Therapeutics (2024) Vol. 46, Iss. 5, pp. 439-440
Closed Access | Times Cited: 8
Showing 8 citing articles:
Improving the management of polycythemia vera patients eligible for cytoreduction: report of a multidisciplinary advisory board
Francesco Ramundo, Elena Rossi, Ketty Peris, et al.
Current Medical Research and Opinion (2025), pp. 1-7
Closed Access | Times Cited: 1
Francesco Ramundo, Elena Rossi, Ketty Peris, et al.
Current Medical Research and Opinion (2025), pp. 1-7
Closed Access | Times Cited: 1
The higher initial dose and accelerated titration regimen of ropeginterferon as a treatment option for certain patients with polycythaemia vera
Albert Qin, Lei Zhang, Jie Jin
British Journal of Haematology (2025)
Open Access
Albert Qin, Lei Zhang, Jie Jin
British Journal of Haematology (2025)
Open Access
PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera
Abdulraheem Yacoub, Ghaith Abu‐Zeinah, Albert Qin, et al.
Annals of Hematology (2025)
Open Access
Abdulraheem Yacoub, Ghaith Abu‐Zeinah, Albert Qin, et al.
Annals of Hematology (2025)
Open Access
Hematologic and molecular responses to ropeginterferon alfa‐2b therapy of polycythemia vera: 48‐week results from a prospective study
Seug Yun Yoon, Sung‐Soo Yoon, Deok‐Hwan Yang, et al.
International Journal of Cancer (2025)
Open Access
Seug Yun Yoon, Sung‐Soo Yoon, Deok‐Hwan Yang, et al.
International Journal of Cancer (2025)
Open Access
A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis
Ghaith Abu‐Zeinah, Albert Qin, Harinder Gill, et al.
Annals of Hematology (2024) Vol. 103, Iss. 9, pp. 3573-3583
Open Access | Times Cited: 2
Ghaith Abu‐Zeinah, Albert Qin, Harinder Gill, et al.
Annals of Hematology (2024) Vol. 103, Iss. 9, pp. 3573-3583
Open Access | Times Cited: 2
Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa‐2b
Shanshan Suo, Rongfeng Fu, Albert Qin, et al.
British Journal of Haematology (2024)
Open Access | Times Cited: 2
Shanshan Suo, Rongfeng Fu, Albert Qin, et al.
British Journal of Haematology (2024)
Open Access | Times Cited: 2
Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b
Albert Qin, Daoxiang Wu, Jason Liao, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Albert Qin, Daoxiang Wu, Jason Liao, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
A Novel Monoclonal Antibody against PD-1 for the Treatment of Viral Oncogene-Induced Tumors or Other Cancer
Xu Xu, Shih-Long Yan, Yi‐Te Yo, et al.
Cancers (2024) Vol. 16, Iss. 17, pp. 3052-3052
Open Access
Xu Xu, Shih-Long Yan, Yi‐Te Yo, et al.
Cancers (2024) Vol. 16, Iss. 17, pp. 3052-3052
Open Access
